Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NiBladder 1 phase 3 trial of SHR-1501 plus BCG versus investigator-selected intravesical chemotherapy in BCG-unresponsive papillary NMIBC
CTR20260597Phase 3Active
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1501, bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jul 2026; status: active.
02
Drugs
SHR-1501bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on CTR20260597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260597.